Who
Ken Takanashi
Director
Company insider
Files Form 4 as: Director and 10% owner, Wave Life Sciences; Director and 10% owner, Satsuma Pharmaceuticals.
In numbers
- Trades disclosed
- 38
- Buys
- 3
- Sells
- 2
- Bought
- $25.6M
- Sold
- $89K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 14 Aug 2015
- Last trade
- 5 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 7 Oct 2026 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Code A | —10,700 at $0.00 | filing |
| 5 Oct 2026filed 7 Oct 2026 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,000 at $0.00 | filing |
| 11 Aug 2026filed 13 Aug 2026 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Sold | $23K3,864 at $6.01 | filing |
| 11 Aug 2026filed 13 Aug 2026 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Sold | $23K3,864 at $6.01 | filing |
| 23 Mar 2026filed 26 Mar 2026 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Code C | —3,901,348 at $0.00 | filing |
| 23 Mar 2026filed 26 Mar 2026 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,901,348 at $0.00 | filing |
| 23 Mar 2026filed 26 Mar 2026 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,901,348 at $0.00 | filing |
| 23 Mar 2026filed 26 Mar 2026 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Code C | —3,901,348 at $0.00 | filing |
| 11 Aug 2025filed 13 Aug 2025 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —76,200 at $0.00 | filing |
| 11 Aug 2025filed 13 Aug 2025 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Code A | —12,700 at $0.00 | filing |
| 5 Aug 2025filed 7 Aug 2025 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Sold | $43K4,872 at $8.75 | filing |
| 12 Aug 2024filed 14 Aug 2024 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,230 at $0.00 | filing |
| 12 Aug 2024filed 14 Aug 2024 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Code A | —16,115 at $0.00 | filing |
| 7 Aug 2023filed 9 Aug 2023 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 8 Jun 2023filed 8 Jun 2023 | Satsuma Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —10,000 at $0.00 | filing |
| 8 Jun 2023filed 8 Jun 2023 | Satsuma Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —20,000 at $0.00 | filing |
| 8 Jun 2023filed 8 Jun 2023 | Satsuma Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | Satsuma Pharmaceuticals | SEC FORM 4 Bought | $20.1M22,053,581 at $0.91 | filing |
| 15 Aug 2022filed 17 Aug 2022 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 3 Jun 2022filed 9 Dec 2022 | Satsuma Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
News
Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026WVE · manilatimes.net · 20 Oct 2026Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026WVE · manilatimes.net · 19 Oct 2026WAVE Life Sciences (NASDAQ:WVE) and Alumis (NASDAQ:ALMS) Head to Head ComparisonWVE · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Ken Takanashi; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.